Cargando…

Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia

Detalles Bibliográficos
Autores principales:	Hashemian, Seyed MohammadReza, Khoundabi, Batoul, Velayati, Ali Akbar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162908/ https://www.ncbi.nlm.nih.gov/pubmed/34217670 http://dx.doi.org/10.1016/j.intimp.2021.107693

Ejemplares similares

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
por: Solaymani-Dodaran, Masoud, et al.
Publicado: (2021)

Oxygenation Efforts for Iranian COVID-19 ARDS Patients: First 5-Day Crisis Experience Scenario
por: Hashemian, Seyed Mohammadreza, et al.
Publicado: (2020)

Efficacy of Early Prone Positioning Combined with Noninvasive Ventilation in COVID-19
por: Hashemian, Seyed Mohammadreza, et al.
Publicado: (2021)

Acute Kidney Injury in ICU Patients Following Non-Cardiac Surgery at Masih Daneshvari Hospital: Joint Modeling Application
por: Khoundabi, Batoul, et al.
Publicado: (2015)

Acute Kidney Injury Risk Factors For ICU Patients Following Cardiac Surgery: The Application of Joint Modeling
por: Khoundabi, Batoul, et al.
Publicado: (2016)

A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19
por: Hashemian, Seyed MohammadReza, et al.
Publicado: (2020)

Beneficial Outcomes of Early Tracheostomy in Patients Requiring Prolonged Mechanical Ventilation
por: Samiei Nasr, Danial, et al.
Publicado: (2020)

Favipiravir: Lack of efficacy during the treatment with SARS-CoV-2 pneumonia: case report
Publicado: (2022)

Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
por: Shinkai, Masaharu, et al.
Publicado: (2021)

Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial
por: Barati, Saghar, et al.
Publicado: (2021)

Non-coding RNAs and Exosomes: Their Role in the Pathogenesis of Sepsis
por: Hashemian, Seyed MohammadReza, et al.
Publicado: (2020)

Favipiravir use for SARS CoV-2 infection
por: Boretti, Alberto
Publicado: (2020)

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2021)

Efficacy of Low-Dose Ciclesonide and Fluticasone Propionate for Mild to Moderate Persistent Asthma
por: Jamaati, Hamidreza, et al.
Publicado: (2015)

Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form
por: Tabarsi, Payam, et al.
Publicado: (2021)

Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients
por: Chen, Ping-Jen, et al.
Publicado: (2021)

Etiology of Respiratory Complications among Iranian HIV Infected Patients
por: Marjani, Majid, et al.
Publicado: (2019)

Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting
por: Reddy, Pavan Kumar, et al.
Publicado: (2022)

Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey
por: ERDEM, Hüseyin Aytaç, et al.
Publicado: (2021)

Prevalence of Oseltamivir-Resistant 2009 H1N1 Influenza Virus among Patients with Pandemic 2009 H1N1 Influenza infection in NRITLD, Tehran, Iran
por: Moradi, Ahmadreza, et al.
Publicado: (2011)

Clinical efficacy and safety evaluation of favipiravir in treating patients with severe fever with thrombocytopenia syndrome
por: Yuan, Yang, et al.
Publicado: (2021)

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates
por: Marlin, Romain, et al.
Publicado: (2022)

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia
por: Ikeda, Mahoko, et al.
Publicado: (2023)

Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone
por: Sood, Shivani, et al.
Publicado: (2021)

PIONEER trial: favipiravir to treat moderate COVID-19
por: Shalhoub, Sarah
Publicado: (2023)

Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir
por: Peng, Qi, et al.
Publicado: (2021)

Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia
por: Al-Muhsen, Saleh, et al.
Publicado: (2022)

The Assessment of the Efficacy and Safety of Favipiravir for Patients with SARS-CoV-2 Infection: A Multicenter Non-randomized, Uncontrolled Single-arm Prospective Study
por: Yanagisawa, Kunio, et al.
Publicado: (2022)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
por: Guner, Rahmet, et al.
Publicado: (2021)

Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS)
por: Hashemian, Seyed MohammadReza, et al.
Publicado: (2021)

Model of the RNA Polymerase Complex of the SARS-CoV-2 Virus with Favipiravir
por: Polyakov, I. V., et al.
Publicado: (2021)

Factors associated with death or intensive care unit admission due to pandemic 2009 influenza A (H1N1) infection
por: Tabarsi, Payam, et al.
Publicado: (2011)

Effectiveness of Borage plus syrup on COVID-19 patients in intensive care units
por: Hashemian, Seyed MohammadReza, et al.
Publicado: (2022)

Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition
por: Takahashi, Hidenori, et al.
Publicado: (2020)

Clinical efficacy of Nafamostat Mesylate in combination with Favipiravir for COVID-19 pneumonia treatment review article
por: Abduljabbar, Maram H.
Publicado: (2021)

Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis
por: Yamada, Kentaro, et al.
Publicado: (2016)

Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase
por: Shannon, A., et al.
Publicado: (2020)

Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?
por: Zhao, Lei, et al.
Publicado: (2021)

Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
por: Negru, Paul Andrei, et al.
Publicado: (2022)

Chloroquine/favipiravir/rituximab: COVID-19-pneumonia, off-label use and lack of efficacy: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l9gcc6f1aova9oshta20ppsea3